Volume | 1,128,866 |
|
|||||
News | - | ||||||
Day High | 23.06 | Low High |
|||||
Day Low | 22.42 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Acadia Pharmaceuticals Inc | ACAD | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
22.52 | 22.42 | 23.06 | 22.85 | 22.60 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
14,918 | 1,128,866 | $ 22.76 | $ 25,688,986 | - | 14.45 - 33.99 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:00:19 | 2 | $ 22.80 | USD |
Acadia Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
3.75B | 164.18M | - | 517.24M | -215.98M | -1.32 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Acadia Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ACAD Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 22.19 | 23.06 | 21.59 | 22.30 | 1,067,910 | 1.00 | 4.51% |
1 Month | 25.10 | 25.57 | 21.58 | 22.69 | 1,219,716 | -1.91 | -7.61% |
3 Months | 26.45 | 27.18 | 20.305 | 23.05 | 1,629,320 | -3.26 | -12.33% |
6 Months | 24.36 | 33.99 | 20.305 | 25.57 | 1,591,968 | -1.17 | -4.8% |
1 Year | 15.62 | 33.99 | 14.45 | 22.72 | 1,517,858 | 7.57 | 48.46% |
3 Years | 53.49 | 57.34 | 12.24 | 22.47 | 1,666,429 | -30.30 | -56.65% |
5 Years | 20.22 | 58.72 | 12.24 | 27.87 | 1,585,376 | 2.97 | 14.69% |
Acadia Pharmaceuticals Description
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. |